The United States reports a record 3000 daily coronavirus disease 2019 (COVID-19) deaths; the House of Representatives passes bill in support of marijuana research; data show rises in prescription drug list prices.
Daily deaths from coronavirus disease 2019 (COVID-19) topped 3000 for the first time in the United States on December 9, The New York Times reports. The new peak comes 1 week after a previous daily record of 2885 deaths was set—a troubling milestone, as so many daily deaths had not been reported in the country since April 15. This nationwide surge also led to the highest average number of deaths reported in the country since April (from 2232 to 2249). At least 288,000 total deaths have been reported in the United States since the pandemic’s onset, more than any other country. Currently, Brazil ranks second for overall COVID-19 mortality, reporting around 179,000 deaths.
The United States House of Representatives passed a bill that would enable scientists to conduct marijuana research in states that have legalized the substance, according to Politico. The bill marks the second piece of marijuana legislation passed by the Democratic-controlled House in recent days, but it was passed with strong bipartisan support. Currently, research on marijuana is based on a few variations grown by the University of Mississippi, as it is the only entity permitted to grow the substance under federal law for research. In addition to creating a new research structure for the drug, the bill would amend the Controlled Substances Act to remove any limitations on researching marijuana and speed up wait times for research marijuana cultivation applications.
New research published in JAMA Network Open found list prices for prescription drugs have more than doubled between 2010 and 2016. Specifically, pricing data from the top 5 patent-protected specialty and 9 traditional brand name medications showed the median wholesale list price rose by 129% within the 6-year window. In addition, investigators found median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. The cross-sectional analysis was based on 14.4 million pharmacy claims made by 1.8 million patients, with the researchers concluding that the increases in drug list prices associated with increased patient out-of-pocket costs may have implications for cost-related nonadherence and insurer payments.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More